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Introduction
Molecular imaging using targeted contrast agents 
has been used to highlight fundamental biological 
mechanism for some time now, and facilitates the de-
velopment of new drugs [1]. It has also proved to be a 
valuable tool for the early detection of molecular and 
cellular events, and for the characterization of molecule 
expression levels involved in inflammation and angio-
genesis process [2-5]. The development of new contrast 
agents in the oncology field focuses on their specific tar-
geting of angiogenesis and their binding to receptors/
molecules such as the αvβ3 integrin, which is highly ex-
pressed on activated endothelial cells in tumor vessels 
[6].
Molecular Ultrasound (US) is an recent imaging ap-
proach that has rapidly found its niche among other 
molecular imaging modalities thanks to its high tempo-
Abstract
Seeking out and identifying imaging biomarkers for early 
cancer diagnosis and the evaluation of patient response to 
therapy requires an improvement in the specificity of imaging 
techniques. This study explores in vivo neo-angiogenesis as-
sessment using molecular mechanisms through target molec-
ular Magnetic Resonance (MR) and Ultrasound (US). In this 
context, our study examines and compares the use of both 
imaging technics, targeting the same integrin in a mouse xeno 
graft tumor model. Following xeno transplantation of human 
renal cell carcinoma (Human A498), thirteen nude mice were 
injected with ανβ3-targeted and non-targeted Contrast Agents 
(CA) for MR and US use, respectively. CA binding to the tar-
geted receptor was measured through Dynamic Susceptibility 
Contrast MR imaging and Differential Targeted Enhancement 
(DTE) US imaging. The specificities and co location of both 
targeted CAs were studied throughout the tumor, in both hypo- 
and hyper-vascularized areas.
One hour postinjection, a significant difference was ob-
served between the signals of targeted and non-targeted 
MR CA (p = 0.03). The DTE-US targeted CA was signifi-
cantly enhanced compared to non-targeted CA (p = 0.002). 
In the hypo- and hyper-vascularized regions of interest, a 
strong correlation was observable between both modalities, 
with values of r10min = 0.86 (p = 0.0003), r30min = 0.85 (p = 
0.0004) and r60min = 0.87 (p = 0.0001).
This study highlights the specificity of each targeted CA. A 
high correlation was noted between MR and US molecular 
imaging for angiogenesis assessment. These two molecular 
imaging modalities may be used interchangeably to monitor 
patient response to anti-angiogenic treatment.
Keywords
Bimodal molecular imaging DCE-US/MRI, Ανβ3- Targeted 
contrast agent, USPIO nanoemulsion, US microbubbles
Abbreviations
CA: Contrast Agents; US: Ultrasound; DTE: Differential 
Targeted Enhancement; MR: Magnetic Resonance; SE: 
Standard Error; Fps: Frames per second; DSC: Dynamic 
Susceptibility Contrast; ROI: Region of Interest
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old) were bred and housed in the Animal Care Facility 
at the Institute Gustave Roussy (Villejuif, France), in ac-
cordance with institutional guidelines for animal wel-
fare. Human A498 renal cell carcinoma (ATCC-HTB-44, 
American Type Culture Collection, Manassas, USA) were 
cultivated in EMEM (Eagle’s Minimum Essential Medi-
um, Gibco Life Technologies, Gaithersburg, MD, USA) 
supplemented with 10% FBS (Fetal Bovine Serum). The 
experiments started 30 days after 3 × 106 cells in 0.2 mL 
matrigel (Corning Corporated, Tewksbury, USA) were 
subcutaneously inoculated into the right flank of the 
mice.
Imaging protocol
Imaging sessions were performed using MR and US, 
each combined with targeted and non-targeted CA that 
had been injected intravenously in the systemic circu-
lation (Figure 1). Targeted and non-targeted protocols 
were performed on the same day (D1) for US experi-
ments, and systematically at a 2-day interval for MR 
experiments (i.e. non-targeted contrast agent injection 
was made on D3 or D5 and finally the targeted contrast 
agent injection was carried out on D3 or D5) to avoid 
any interaction between the MR- and US-targeted CAs.
Mice were anesthetized before each imaging ses-
sion by the inhalation of isoflurane (2%) in room air (1.5 
L/min). Their body temperature was monitored and 
maintained constant using a heated platform during US 
acquisitions or a constant warm air flow during MR ac-
quisitions. Table 1 shows the number of mice used to 
evaluate ανβ3-targeted contrast agents and character-
ize their affinity to the ανβ3 sites.
Molecular MR imaging
MR imaging was performed using a clinical 1.5 T 
scanner (Achieva, Philips Healthcare, Best, The Nether-
lands) equipped with a 60 cm bore and a conventional 
23 mm diameter microscopy surface coil for reception. 
Relaxation rate R2
* measurements were made using a 
3D T2
*-weighted gradient-echo multi-echo sequence, 
selected for its sensitivity to apparent transverse relax-
ation effects induced by USPIO. Dynamic Susceptibility 
ral resolution and ease of use [2]. Dynamic Susceptibil-
ity Contrast (DSC)-Magnetic Resonance (MR) imaging 
uses Ultra-Small Super Paramagnetic Iron Oxide (USPIO) 
Contrast Agent (CA) to provide information on tumor 
vascularization and hemodynamic status.
With the development of targeted agents binding to 
specific receptors, DSC-MR imaging can also provide mo-
lecular information in intra- and extra-vascular conditions; 
this has the advantage of requiring low CA concentrations 
making it possible to probe specific molecular events [7].
The increasing development of novel targeted thera-
pies to treat tumors necessitates a parallel development 
of technologies that can determine their potential effi-
cacy, and thus facilitate therapeutic protocol planning. 
Efforts are also being made to assess and quantify bio-
markers of treatment response that could provide infor-
mation on the location and extent of cancer, including 
tissue characteristics or spatial heterogeneity [2,8].
The aim of this work was to evaluate the feasibility 
of detection of molecular events and compare in vivo 
quantitative US and MR molecular imaging protocols.
The pilot study was performed on renal cell carci-
noma xeno grafts in mice and was designed with two 
main goals in mind: 1) To evaluate the specificity of two 
contrast agents (MR iron oxide nanoemulsion and US 
microbubbles), both of which were specifically designed 
to target ανβ3 integrin and 2) To compare the colocal-
ization of molecular expression of the targeted integrin 
obtained by specific MR and US contrast agent acquisi-
tions, respectively (summarized in Table 1).
Materials and Methods
All experiments followed the guidelines of the Euro-
pean Convention for the Protection of Vertebrate Ani-
mals used for experimental and other scientific purpos-
es, and were approved by the Animal Research Commit-
tees of the relevant laboratories, C2EA-26 and C2EA-44 
(both registered at the French research ministry).
Mice and tumor model
Ten female immune deficient nude mice (6-8 weeks 
Table 1: Summary of experimental protocol - evaluation of MR and US CA specificity - evaluation of targeted MR and US CA 
colocalization.
Mouse MR US
Non-targeted CA Targeted CA Non-targeted CA Targeted CA
1 × +
2(*) × × × ×
3 + × ×
4(*) × × × ×
5 + × ×
6(*) × × × ×
7 × +
8 ×
9 ×
10 ×
*Same mice for US specificity, MR specificity, and targeting protocols; × Same mice for MR and US CA co-localization; + Dead mouse.
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MHz center frequency (MS-250, Visual Sonics). Tumor 
volumes were measured using 2D B-mode imaging, as 
described in the literature [9]. 2D Differential Targeted 
Enhancement Ultrasound (DTE-US) imaging sessions 
were performed on the maximal transverse section of 
each tumor using contrast pulse sequencing technolo-
gy, to reach the nonlinear signal produced by microbub-
bles. Images were collected at a high spatial resolution 
(lateral and axial resolution of 165 and 75 µm, respec-
tively), with 4% transmission power, 5 frames per sec-
ond (fps), and a dynamic range of 40-dB [9].
Micro Marker ανβ3-targeted and control (IgG) mi-
crobubbles (Visual Sonics, Toronto) with a diameter of 
approximately 2-3 µm were manually injected via the 
retro-orbital vein (50 µL per injection, injection time: 2 
seconds). A 30-minute interval between the two injec-
tions allowed the first CA to be cleared from the vascu-
lature [9]. After each CA injection, the signal intensity 
was recorded as a function of time during the wash-in 
contrast enhancement. CA targeting was then observed 
10 minutes after the bolus injection in order to allow 
the targeted microbubbles to bind to their endothelial 
molecular receptors [9], and a series of images was re-
corded over 30 seconds. Using the destruction/replen-
ishment approach [10], a continuous high-powered de-
structive pulse (100% transmit power for 1 s) was then 
applied to destroy all microbubbles within the US beam 
elevation. Images were recorded while freely circulating 
CA replenished the tumor vessels. Data were then ana-
Contrast (DSC)-MR was performed repeatedly for one 
hour after the CA injection. R2
* mapping (3D 0.5 mm 
isotropic sequence, TR/TE/echo spacing = 90/5.9/9.7 m 
sec, 6 echoes, 0.3 × 0.3 × 0.5 mm3 reconstruction voxel 
size, 220 Hz/pix, Tacq = 4.2 min) was carried out before 
and after the injection in the caudal vein of 100 µmol 
Fe/kg USPIO-based nanoemulsion functionalized with 
RGD-binding ανβ3 (P4000, referred to as E1 in patent 
application US 2015/0320889 A1, entitled ‘Vectorised 
magnetic emulsion’, and filed on Nov. 12, 2015). Identi-
cal R2
* mapping protocol was also carried out before and 
after the injection of a non-functionalized control na-
noemulsion (P3999, referred to as E1T in patent appli-
cation US 2015/0320889). Nanoparticle diameters were 
approximately 190 nm. These contrast agents are also 
commercialized by Chematech (France). As generally 
assumed in a first approximation, transverse relaxation 
rate R2
* = 1/T2
* = R2,0
* + r2
* [Fe] is linear with concentra-
tion, and relaxivity is r2
*~210 mM-1.s-1 (patent applica-
tion US 2015/0320889 A1). All images were processed 
with Matlab software (2011B, Math works, USA). Mean 
pre- and post-injection variations, or ΔR2
* (R2
*
pre- R2
*
post), 
were calculated and monitored for 1 hour to quantify 
CA concentration, which directly reflects the binding to 
the targeted receptor.
Contrast-enhanced molecular US
All US acquisitions were performed on a dedicated 
system for small animal imaging (VEVO®2100, Visual 
Sonics, Canada), using a linear array probe with a 21 
         
(a) DTE-US
(b) DSE-MRI
Pre- and Post- CA destructionPre injection
Pre injection Post injection
US acquisition
10 ‘ Post injection
US acquisition DTE measurement
Time (min)IV CA
Injection
R2* acquisition R2* acquisitions
0 10
0             10           20           30           40          50           60
Figure 1: Experimental (a) US; (b) MR protocols. The US protocol began with the CA injection. Ten minutes after the bolus 
injection, series of images were recorded for approximately 30 seconds. Using the destruction/replenishment approach, 
a continuous high-powered destructive pulse was then applied to destroy all microbubbles within the US beam elevation. 
Images were recorded while freely circulating CA replenished the tumor vessels. The MR protocol began with localization 
and included a repeated 3D R2
*-weighted sequence for CA quantification. The R2*-weighted sequence was then performed 
pre-contrast (t = 0 min), and was repeated every 7 minutes until 1 hour post-administration.
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alcohol (Cryomatrix OCT compound, Thermo Fisher Sci-
entific, USA), then frozen in liquid nitrogen. The tumors 
were cut into 7-8 μm-thick sections located as close as 
possible to the maximal transverse section imaged by 
DTE-US and DSC-MR. Sections were stained with Hema-
toxylin, Eosin and Saffron (HES) and observed to verify 
tissue integrity.
To verify the presence of β3 on the cells of the vas-
cular endothelium of renal carcinoma, cover slips were 
incubated overnight at 4 °C with anti-human rabbit β3 
(1:1000; 04-1060, Millipore) in TNB buffer as a primary 
antibody, then incubated for 2 h with HRP-conjugated 
goat anti-mouse IgG (1:1000; 111-036-047, Jackson Im-
munoResearch) in TNB buffer as a secondary antibody. 
Given that the tumor tissue could also express the β3 
integrin, β3/CD31 double labeling was carried out to 
demonstrate the labeling of the integrin in the vascu-
lar endothelium. CD31 was revealed using anti-mouse 
rat CD31 (1:50; 553370, BD Biosciences) then goat an-
ti-rat IgG coupled to Alexa Fluor 555 (1:200; A-21434, 
Life Technologies). The β3 was amplified using the TSA 
kit (NEL749A001KT, Perkin Elmer) and revealed by 
FITC-Streptavidin (1:200, STAR2B, AbD Serotec). The 
nuclei were labeled with DAPI (Atlantic Bone Screen, 
France). Nuclear staining with DAPI allowed the iden-
tification of tissue structure and quality. Tissue fluores-
cence was observed under a multiphoton microscope 
lyzed using the VEVO®2100 software to quantify the DTE 
value (arbitrary unit) within specific Regions of Interest 
(ROIs), calculated by using the difference between the 
mean pre- and post-destruction signal intensities. DTE 
value is an indicator of the number of microbubbles that 
adhere to molecular endothelial receptors.
Evaluation of targeted MR and US contrast agent 
colocalization
MR data were colocalized on the US 2D acquisitions 
to choose the closest slice in the 3D MR-acquisition vol-
ume (R2
*-weighted images), (Figure 2a). To compare 
DTE-US imaging to DSC-MR imaging, mean values of 
DTE and relaxation rates ΔR2
* were determined in whole 
tumor ROI (ROI-1) and multiple intratumoral ROI (ROI 2 
to 7) to reflect the heterogeneity of intratumoral mo-
lecular expression. ROI 2 to 5 was manually drawn to 
facilitate the location (Figure 2b). The two remaining 
ROIs (ROI 6 and 7) were determined as the two extrema 
of targeted contrast agent imaging, i.e. they were hypo- 
(ROI-6) and hyper- (ROI-7) contrast enhanced. ROIs all 
measured 3.14 mm2 (circle with a radius of 1 mm).
Immunofluorescence
Immediately after the last MR imaging session, all 
five tumors were extracted, embedded in a OCT gel-like 
medium consisting of polyethylene glycol and polyvinyl 
         
a.
b.
3D MR -acquisition
volume
MR closest slice on
the US 2D
acquisition
DSC-MR DTE US imaging
ROI 3 ROI 4
ROI 7
ROI 6
ROI 1
ROI 2 ROI 5
mouse
skintumor
Figure 2: Schematic of data segmentation and ROI delimitation a) MR data colocalization on the US 2D acquisitions (B-mode) 
to choose the closest slice in the 3D MR-acquisition volume (R2
*-weighted images, first echo); b) Bi-dimensional Regions of 
Interest (ROIs) were defined manually to delimit the whole tumor (ROI 1), ¼ of the tumor section (ROI 2 to 5), hyper- (ROI 6) 
and hypo- (ROI 7) vascularized areas. The last two ROIs systematically measured 3.14 mm2 (circle with a radius of 1 mm). 
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cally analyzed using the Pearson’s correlation coefficient 
(r) for normally distributed data, and the Spearman rank 
coefficient correlation was used in the absence of nor-
mal distribution. The significance level of the correla-
tion was determined with corresponding Pearson and 
Spearman tests. The ΔR2
* and DTE values were not nor-
(SP8, Leica). Regions of interest were photographed at 
a magnification of x63 through an oil immersion lens.
Statistical analysis
All continuous measurements were expressed as 
mean ± standard deviation. Correlations were statisti-
         
Pre-injection
Post-injection
DTE-US DSC-MR
a.
b.
c.
d.
Figure 3: Molecular US imaging in harmonic mode carried out a) pre-injection; b) 10 minutes postinjection of targeted 
microbubbles. First echo of DSC-MR imaging carried out; c) preinjection; d) 10 minutes postinjection of targeted USPIO 
nanoemulsion. The MR hyposignal is due to the presence of USPIO nanoemulsion, while microbubbles lead to a hypersignal 
on US acquisition.
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non-targeted CA
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Figure 4: ΔR2* mean values (± Standard Error SE), for targeted (square) and non-targeted (diamond) CA as a function of 
time. ΔR2* values became significantly different between targeted and non-targeted CA for all acquisitions performed every 
7 minutes between 37 and 60 minutes postinjection (p = 0.03, Wilcox on test for paired samples), thus providing the most 
appropriate imaging window to image specific binding. At 1 hour postinjection, ΔR2* measurement for targeted CA was 
16.5 ± 3.9 s-1, significantly different from the values recorded for non-targeted CA, namely 5.8 ± 1.8 s-1 (p = 0.03, Wilcox on 
test for paired samples). 
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jection from 10 to 60 minutes at intervals of 7 minutes, 
in order to determine the optimal time at which MR 
imaging parameters should be compared in terms of 
CA binding specificity. Figure 4 shows the ΔR2
* mean 
values (± Standard Error SE) for targeted (square) and 
non-targeted (diamond) CA as a function of time. ΔR2
* 
values became significantly different between targeted 
and non-targeted CA for all acquisitions performed 37 
minutes postinjection and later (p = 0.03), thus provid-
ing the imaging window to capture specific binding. At 
1 hour postinjection, the ΔR2
* value for targeted CA was 
16.5 ± 3.9 s-1; significantly different to that of non-tar-
geted CA, i.e. 5.8 ± 1.8 s-1 (p = 0.03).
Figure 5 shows the mean (± SE) US contrast signal 
intensities evaluated 10 minutes after the CA injection, 
before and after targeted and non-targeted CA destruc-
mally distributed and were therefore compared using 
a non-parametric Wilcox on signed-rank test. A p-value 
of less than 0.05 was considered statistically significant.
Results
Figure 3 shows an example of the same tumor imaged 
by MR (R2
*-weighted scan, first echo with a Signal to Noise 
Ratio of 70) and DTE-US before and after the targeted CA 
injection. S although the signal was homogeneous before 
injection in both MR and US images, strong heterogeneity 
was observed after the injection of the CA, with signal en-
hancement in US sessions and an R2
* increase in MR imag-
ing indicating molecular ανβ3 expression.
MR and US contrast agent specificity
DTE-US measurements at the tenth minute postin-
jection were compared to ΔR2
* measurements post-in-
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Figure 5: Mean (± SE) US contrast signal intensities evaluated 10 minutes after the CA injection, before and after targeted and 
non-targeted CA destruction. Non-significant difference was observed in the signal for non-targeted CA, whereas a significant 
decrease was observed for the targeted CA (p = 0.03, Wilcox on test), indicating the binding of the specific CA. DTE values 
(mean ± SE), calculated as the difference between US signal intensities before and after CA destruction, were 260.5 ± 66.0 
a.u. for the non-targeted CA and 2601.5 ± 488.3 a.u. for the targeted CA. Significantly different changes in contrast were 
observed between US targeted and non-targeted CA (p = 0.002, Wilcox on test for paired samples).
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Figure 6: Tumoral size evaluation from MR and US imaging, where r = 0.99, p < 0.001 (Pearson test). The tumor area 
measured from MR imaging was 25% higher than that estimated using US.
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(p = 0.0005). The mean values of ΔR2
* and DTE measured 
for ROI 1 to 5 were not significantly correlated, even 
for different post-injection times (r < 0.71). The strong 
correlation was observed on the specific ROIs, i.e., the 
hypo- and hyper-vascularized areas (ROI 6 and ROI 7, 
Figure 7 with respectively r10min = 0.86 (p = 0.0003); r30min 
= 0.85 (p = 0.0004) and r60min = 0.87 (p = 0.0001).
Immunofluorescence
The observations acquired by optical microscopy in 
tissue images (Figure 8) indicated the colocalization of 
β3 with CD31, confirming the presence of integrin on 
the endothelial cells of this A498 RCC tumor model. 
Several integrins are involved in cancer progression but 
most of them, such as αvβ3, are over expressed, mak-
ing them difficult to quantify [6,11,12]. We successfully 
evaluated colocalization using Imaris (Bit plane Scientif-
ic Software) to quantify the percentage of colocalization 
between the 2 CD31 and β3 markers, and found that 
colocalized β3/CD31 areas made up 30.6% of the vas-
culature area.
Discussion
The contrast agents, i.e. iron oxide nanoemulsion 
(DSC-MR) and microbubbles (DTE-US), were both func-
tionalized to target the same integrin (ανβ3) for pre-
clinical oncology applications, and both were shown to 
provide specific targeting [13]. The novelty of this work 
was to make a fair comparison of molecular imaging ap-
proaches seeking to identify the colocalization of angio-
genesis target, using different contrast agents with dif-
ferent fixation mechanisms. These results highlight the 
reliability of molecular imaging for angiogenesis.
An entire analysis protocol was specifically developed 
here to colocalize the US 2D acquisition to the closest 
slice in the 3D MR-acquisition volume. This protocol was 
combined with a systematic segmentation of the different 
tumor areas where ΔR2
* and DTE were calculated. In this 
way, we ensured the closest and thus fairest possible com-
parison between MR and US results, enabling region-based 
comparison among imaging modalities.
First, the comparison of these specific contrast agents 
tion. The signal did not change in the case of non-tar-
geted CA, but a significant decrease was observed for 
the targeted CA (p = 0.03), indicating the binding of the 
specific CA. DTEnon-targeted CA values were of 260 ± 66 a.u. 
compared to 2601 ± 488 a.u for DTEtargeted CA, indicating 
significantly different contrast enhancement (p = 0.002).
Molecular US and MR colocalization
The manually segmented tumor areas correlated 
well between the two imaging modalities (r = 0.99, 
p < 0.001, Figure 6), as expected. The tumor area mea-
sured using MR-imaging was 25% larger than the tumor 
area measured using US; this difference may be due to 
different manual tracing.
The correlation coefficient r was evaluated for both 
ΔR2
* and DTE values measured in all seven specific ROIs 
for the different post-injection times in the DSC-MR 
protocol. The best correlations in all the ROIs were ob-
tained at 60 minutes postinjection, with r values of 0.52 
         
DTE
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Figure 7: a) Maximum correspondence between US and MR parameters (r = 0.875, Pearson test p < 1.10-5) was observed for 
the specific ROIs, i.e., the hypo- and hyper-vascularized areas (ROI 6 and ROI 7), defined in b) US and c) MR acquisitions at 
60 minutes after injection.
         
Figure 8: Examples of immunofluorescence merged imag-
es for β3 (green), CD31 (red), and DAPI (blue) obtained 
using multi photon microscopy in A498 tumor sections. Bar 
= 50 µm.
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of MR and US imaging to evaluate the early response of 
different therapeutic agents in renal cell carcinoma [15]. 
Some studies suggested that RGD peptide could not ne-
cessarily reflect the change of integrin ανβ3 expression 
on neoangiogenesis detection [16,17]. Consequently, the 
real potential of RGD peptide in therapy response moni-
toring needs to be confirmed with well-designed clinical 
investigations Beyond this limit of targeted-CAs specificity, 
the main benefits of the molecular US approach are its ac-
cessibility and low cost. Limitations linked to operator de-
pendency can often be overcome with practice. The eval-
uation of early response to treatment could be achieved 
by improving methods for the detection and evaluation 
of tumors and identifying the expression levels of cell sur-
face receptor such as integrins, thus permitting doctors to 
select the most efficient type of treatment for each case. 
Combining this early response to treatment with an acces-
sible imaging technique such as molecular US would be a 
major gain for personalized care.
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with the non-targeted contrast agents within each im-
aging session yielded significant differences (MR - Figure 
4, US - Figure 5). The dynamic contrast provided by MR 
imaging allowed the evaluation to take place over a suf-
ficiently long time scale to observe the CA kinetic, which 
was not the case for US acquisitions. US experiments 
gave access to measurement of the quantity of target-
ed microbubbles at only one time point, i.e. 10 minutes 
postinjection, as recommended by Van Rookie, et al. 
[14]. The optimal window to perform MR imaging was 
assessed (Figure 4), and the targeted MR signal became 
significantly different from the non-targeted one after 
37 minutes. The MR CA injected for this study had larger 
diameters and stronger relaxivity than those commonly 
used, and appears to be a promising tool for molecular 
imaging. These molecular MR CAs, based on nano-ob-
jects and containing a high payload of contrast-gener-
ating metals (USPIO in this study), are now sensitive 
enough for use in target-specific imaging. In light of the 
sensitivity (r2
*~210 mM-1.s-1) and the observed average 
specific ΔR2
* (close to 10 s-1) recorded, we can consider 
that approximately 50 µM concentration of iron (or a 50 
pM concentration of droplets) was measurable, which is 
within the range of receptor concentrations.
Secondly, a good correlation was observed between 
specific targeted MR and US signal, with a high correlation 
coefficient of 0.87 at 60 minutes after injection Figure 7.
The results highlighted the high colocalization of 
MR and US targeted contrast agents in vivo, despite 
differences in their respective sizes (190 nm vs. 2-3 µm 
diameters) and fixation mechanisms. MR nanoemul-
sion was targeted with RGD, while US CA was targeted 
with antibodies. Thus, the high colocalization observed 
in this study demonstrated the reliability of molecular 
imaging, whatever imaging modalities, MR or US. How-
ever, simultaneous imaging by both modalities does 
not provide any evidence that could explain the funda-
mental biological fixation mechanism. In particular, the 
different CA sizes led us to expect the observation of 
some integrins expressed exclusively on activated endo-
thelial cells from vessels with the DTE-US, and integrins 
expressed on tumor cells after extravasation of the MR 
AC. These differences in CA behavior might explain ob-
servations made in other ROIs.
The localization of β3 was assessed and confirmed by 
immunofluorescence within the vessels and within the 
extracellular matrix. The difficulty of implementing integ-
rin labelling and observation makes it impossible to study 
slices thicker than 20 to 30 µm, which would allow a more 
robust observation and possible quantification within the 
vessels. Nevertheless, the multi-staining DAPI/CD31/β3 
was optimized to allow high quality visualization.
Finally, our study highlights the equivalence of molec-
ular DTE-US and DSC-MR imaging in terms of specificity 
and CA localization. This approach has already allowed the 
prediction of response to targeted therapies by the use 
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